The stock of Integra Lifesciences Holdings Corp (NASDAQ: IART) has decreased by -6.71 when compared to last closing price of 29.38.Despite this, the company has seen a loss of -13.34% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-18 that PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company’s first quarter 2024 financial results to Monday, May 6, 2024. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. EDT.
Is It Worth Investing in Integra Lifesciences Holdings Corp (NASDAQ: IART) Right Now?
The price-to-earnings ratio for Integra Lifesciences Holdings Corp (NASDAQ: IART) is above average at 32.50x, Company’s 36-month beta value is 1.17.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 5 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for IART is 66.12M, and currently, short sellers hold a 3.95% ratio of that floaft. The average trading volume of IART on April 25, 2024 was 739.39K shares.
IART’s Market Performance
The stock of Integra Lifesciences Holdings Corp (IART) has seen a -13.34% decrease in the past week, with a -18.79% drop in the past month, and a -34.41% fall in the past quarter. The volatility ratio for the week is 4.82%, and the volatility levels for the past 30 days are at 2.92% for IART. The simple moving average for the last 20 days is -16.07% for IART’s stock, with a simple moving average of -31.04% for the last 200 days.
Analysts’ Opinion of IART
Many brokerage firms have already submitted their reports for IART stocks, with Citigroup repeating the rating for IART by listing it as a “Neutral.” The predicted price for IART in the upcoming period, according to Citigroup is $38 based on the research report published on April 03, 2024 of the current year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see IART reach a price target of $49, previously predicting the price at $40. The rating they have provided for IART stocks is “Overweight” according to the report published on December 05th, 2023.
CL King gave a rating of “Buy” to IART, setting the target price at $50 in the report published on November 14th of the previous year.
IART Trading at -24.10% from the 50-Day Moving Average
After a stumble in the market that brought IART to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.62% of loss for the given period.
Volatility was left at 2.92%, however, over the last 30 days, the volatility rate increased by 4.82%, as shares sank -21.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.57% lower at present.
During the last 5 trading sessions, IART fell by -13.03%, which changed the moving average for the period of 200-days by -33.39% in comparison to the 20-day moving average, which settled at $32.29. In addition, Integra Lifesciences Holdings Corp saw -37.06% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IART starting from DAVIS ROBERT T. JR., who sale 8,348 shares at the price of $36.59 back on Mar 06 ’24. After this action, DAVIS ROBERT T. JR. now owns 49,893 shares of Integra Lifesciences Holdings Corp, valued at $305,492 using the latest closing price.
Mosebrook Jeffrey, the SVP, Fin & PAO of Integra Lifesciences Holdings Corp, sale 1,177 shares at $44.46 during a trade that took place back on Aug 09 ’23, which means that Mosebrook Jeffrey is holding 23,458 shares at $52,329 based on the most recent closing price.
Stock Fundamentals for IART
Current profitability levels for the company are sitting at:
- 0.09 for the present operating margin
- 0.58 for the gross margin
The net margin for Integra Lifesciences Holdings Corp stands at 0.04. The total capital return value is set at 0.04. Equity return is now at value 3.99, with 1.77 for asset returns.
Based on Integra Lifesciences Holdings Corp (IART), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at 0.09. The debt to equity ratio resting at 0.95. The interest coverage ratio of the stock is 2.33.
Currently, EBITDA for the company is 297.59 million with net debt to EBITDA at 7.57. When we switch over and look at the enterprise to sales, we see a ratio of 2.3. The receivables turnover for the company is 5.94for trailing twelve months and the total asset turnover is 0.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.45.
Conclusion
In a nutshell, Integra Lifesciences Holdings Corp (IART) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
